An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically
Phase of Trial: Phase IV
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Takeda
- 12 Apr 2018 Planned End Date changed from 31 Mar 2018 to 5 Feb 2019.
- 12 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 5 Feb 2019.
- 09 Feb 2018 Planned End Date changed from 23 Feb 2018 to 31 Mar 2018.